ClinicalTrials.gg
CompletedNCT02447393Updated Aug 3, 2017

Phase 1 Study of Levocetirizine

A Phase 1 interventional study of levocetirizine and cetirizine in Dermatitis, sponsored by GlaxoSmithKline. Completed at 1 site in Japan. Open to male participants aged 20 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-03.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Mar 2008, registered Jun 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Dermatitis by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dermatitis · GlaxoSmithKline.

Enrollment
10th of 11
20 · median 79
Started
2008
with 3 others
Phase 1
4 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Dermatitis by GlaxoSmithKline, this one is the 10th largest by enrollment, is one of 4 that started in 2008, is one of 4 in phase 1, and was the 6th registered.

Dermatitis

238 studies on the registry are indexed under Dermatitis; 33 are open to participants now.

Browse Dermatitis studies →

Open to participants now

None of the 11 studies in Dermatitis by GlaxoSmithKline is open now. The open studies under Dermatitis, anywhere →

Who these studies take

Of the 22 Dermatitis studies recruiting now, 11 (50%) set no upper age limit and 8 (36%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 20 Years to 64 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Dermatitis by GlaxoSmithKline as a file.
02

Study summary

This is a single center, single blind, single dose, randomized, partial cross-over study to confirm bioequivalence between levocetirizine and cetirizine.

03

Conditions studied

  • Dermatitis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy subjects are defined as individuals who are free from illness or disease as determined by their medical history, physical examination, laboratory studies, and other tests.
  2. Body weight ≥ 50 kg and within the range 18.50-25.00 kg/m2 inclusive.
  3. Non-smokers (at least 6 months).
  4. Clinical laboratory tests data obtained at screening meet the following:

    (GOT), ALT(GPT), total-, BUN, creatinine, uric acid,: below the upper normal range

  5. Normal 12-lead EGC finding at screening; \<450msec
  6. Capable of giving written , which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

Exclusion Criteria:

  1. The subject has any abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
  2. The subject has an allergy for any drug or idiosyncrasy.
  3. The subject has a history of allergic rhinitis.
  4. The subject has a history or presence of clinically significant gastrointestinal, hepatic or renal disease or other condition known to interfere with absorption, distribution, metabolism or elimination of drugs.
  5. The subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an or a non-investigational drug or device.
  6. The subject has participated in a clinical study with an investigational or a non-investigational drug or device during the previous 4 months.
  7. The subject has a history or current conditions of drug abuse or alcoholism.
  8. History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink = 150mL of wine or 360mL of beer or 45mL of 80 proof distilled spirits).
  9. The subject is positive for urine drug screening.
  10. The subject is positive for syphilis, HBs antigen, antibody, antibody, HTLV-1 antibody.
  11. The subject has donated a unit of blood ">400mL" within the previous 4 months or ">200mL" within the previous 1 month.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Other
    levocetirizine

    Study Drug

    Drug: levocetirizine

  • Other
    cetirizine

    Study Drug

    Drug: cetirizine

  • Other
    placebo

    Study Drug

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-48 of levocetirizine

    Area Under the time-concentlation curve

    Time frame: predose,0.25,0.5,1,1.5,2,3,4,6,9,12,16,24,36, 48 hours post-dose

  2. Cmax of levocetirizine

    maximum concentration

    Time frame: predose,0.25,0.5,1,1.5,2,3,4,6,9,12,16,24,36, 48 hours post-dose

Secondary outcomes

  1. Number of Adverse events

    Time frame: predose,1,24 48 hours post-dose

  2. Changes in clinical laboratory tests

    Time frame: predose,24,48 hours post-dose

  3. Changes in vital signs

    Time frame: predose,1,24,48 hours post-dose

  4. Changes in 12-lead ECG.

    Time frame: predose,1,24,48 hours post-dose

07

Study locations

1 site
  • GSK Investigational Site
    Kagoshima, 890-0081, Japan
08

References and documents

Publications

  • Hiroko Ino, Shigeru Nohda, Shuji Miki, Kastutoshi Hara, Toshiyasu Hirama. Comparison of levocetirizine pharmacokinetics, following a single dose of levocetirizine alone or as cetirizine in Japanese healthy male volunteers . [Jpn J Clin Pharmacol Therapeut]. 2010;41(6):309.
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2008 to primary completion in Apr 2008, 1 month.

Of 13 phase 1 interventional studies under Dermatitis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2011
First posted
May 18, 2015
StartActual
Mar 18, 2008
Primary completionActual
Apr 30, 2008
CompletionActual
Apr 30, 2008
Last update
Aug 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02447393
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 18, 2015
Start date
Mar 18, 2008
Primary completion
Apr 30, 2008
Completion
Apr 30, 2008
Last update
Aug 3, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levocetirizine · Cetirizine

Start the discussion